Comparative effectiveness of guidelines for the management of hyperlipidemia and hypertension for type 2 diabetes patients.
Several guidelines to reduce cardiovascular risk in diabetes patients exist in North America, Europe, and Australia. Their ability to achieve this goal efficiently is unclear.Decision analysis was used to compare the efficiency and effectiveness of international contemporary guidelines for the manag...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2011-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3026790?pdf=render |
| _version_ | 1818953208539643904 |
|---|---|
| author | Nilay D Shah Jennifer Mason Murat Kurt Brian T Denton Andrew J Schaefer Victor M Montori Steven A Smith |
| author_facet | Nilay D Shah Jennifer Mason Murat Kurt Brian T Denton Andrew J Schaefer Victor M Montori Steven A Smith |
| author_sort | Nilay D Shah |
| collection | DOAJ |
| description | Several guidelines to reduce cardiovascular risk in diabetes patients exist in North America, Europe, and Australia. Their ability to achieve this goal efficiently is unclear.Decision analysis was used to compare the efficiency and effectiveness of international contemporary guidelines for the management of hypertension and hyperlipidemia for patients aged 40-80 with type 2 diabetes. Measures of comparative effectiveness included the expected probability of a coronary or stroke event, incremental medication costs per event, and number-needed-to-treat (NNT) to prevent an event. All guidelines are equally effective, but they differ significantly in their medication costs. The range of NNT to prevent an event was small across guidelines (6.5-7.6 for males and 6.5-7.5 for females); a larger range of differences were observed for expected cost per event avoided (ranges, $117,269-$157,186 for males and $115,999-$163,775 for females). Australian and U.S. guidelines result in the highest and lowest expected costs, respectively.International guidelines based on the same evidence and seeking the same goal are similar in their effectiveness; however, there are large differences in expected medication costs. |
| first_indexed | 2024-12-20T10:02:37Z |
| format | Article |
| id | doaj.art-14f6d7ed456b43a689489ab255327d4c |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-20T10:02:37Z |
| publishDate | 2011-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-14f6d7ed456b43a689489ab255327d4c2022-12-21T19:44:19ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0161e1617010.1371/journal.pone.0016170Comparative effectiveness of guidelines for the management of hyperlipidemia and hypertension for type 2 diabetes patients.Nilay D ShahJennifer MasonMurat KurtBrian T DentonAndrew J SchaeferVictor M MontoriSteven A SmithSeveral guidelines to reduce cardiovascular risk in diabetes patients exist in North America, Europe, and Australia. Their ability to achieve this goal efficiently is unclear.Decision analysis was used to compare the efficiency and effectiveness of international contemporary guidelines for the management of hypertension and hyperlipidemia for patients aged 40-80 with type 2 diabetes. Measures of comparative effectiveness included the expected probability of a coronary or stroke event, incremental medication costs per event, and number-needed-to-treat (NNT) to prevent an event. All guidelines are equally effective, but they differ significantly in their medication costs. The range of NNT to prevent an event was small across guidelines (6.5-7.6 for males and 6.5-7.5 for females); a larger range of differences were observed for expected cost per event avoided (ranges, $117,269-$157,186 for males and $115,999-$163,775 for females). Australian and U.S. guidelines result in the highest and lowest expected costs, respectively.International guidelines based on the same evidence and seeking the same goal are similar in their effectiveness; however, there are large differences in expected medication costs.http://europepmc.org/articles/PMC3026790?pdf=render |
| spellingShingle | Nilay D Shah Jennifer Mason Murat Kurt Brian T Denton Andrew J Schaefer Victor M Montori Steven A Smith Comparative effectiveness of guidelines for the management of hyperlipidemia and hypertension for type 2 diabetes patients. PLoS ONE |
| title | Comparative effectiveness of guidelines for the management of hyperlipidemia and hypertension for type 2 diabetes patients. |
| title_full | Comparative effectiveness of guidelines for the management of hyperlipidemia and hypertension for type 2 diabetes patients. |
| title_fullStr | Comparative effectiveness of guidelines for the management of hyperlipidemia and hypertension for type 2 diabetes patients. |
| title_full_unstemmed | Comparative effectiveness of guidelines for the management of hyperlipidemia and hypertension for type 2 diabetes patients. |
| title_short | Comparative effectiveness of guidelines for the management of hyperlipidemia and hypertension for type 2 diabetes patients. |
| title_sort | comparative effectiveness of guidelines for the management of hyperlipidemia and hypertension for type 2 diabetes patients |
| url | http://europepmc.org/articles/PMC3026790?pdf=render |
| work_keys_str_mv | AT nilaydshah comparativeeffectivenessofguidelinesforthemanagementofhyperlipidemiaandhypertensionfortype2diabetespatients AT jennifermason comparativeeffectivenessofguidelinesforthemanagementofhyperlipidemiaandhypertensionfortype2diabetespatients AT muratkurt comparativeeffectivenessofguidelinesforthemanagementofhyperlipidemiaandhypertensionfortype2diabetespatients AT briantdenton comparativeeffectivenessofguidelinesforthemanagementofhyperlipidemiaandhypertensionfortype2diabetespatients AT andrewjschaefer comparativeeffectivenessofguidelinesforthemanagementofhyperlipidemiaandhypertensionfortype2diabetespatients AT victormmontori comparativeeffectivenessofguidelinesforthemanagementofhyperlipidemiaandhypertensionfortype2diabetespatients AT stevenasmith comparativeeffectivenessofguidelinesforthemanagementofhyperlipidemiaandhypertensionfortype2diabetespatients |